To include your compound in the COVID-19 Resource Center, submit it here.

Advocacy group meeting with Novartis to discuss price for CAR T

Patients For Affordable Drugs said that Novartis AG (NYSE:NVS; SIX:NOVN) will meet with the advocacy group to discuss the pricing of the pharma's acute lymphoblastic leukemia therapy tisagenlecleucel-T (CTL019). The group sent a letter to Novartis CEO Joseph Jimenez, requesting the meeting and called on the pharma

Read the full 471 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers